Active Ingredient History

  • Now
Secobarbital sodium, a barbiturate, is FDA approved for the treatment of insomnia and for pre-anesthetic use. This drug binds at a distinct site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. Adverse reactions are drowsiness, lethargy, hangover, paradoxical excitement in elderly patients, somnolence. Rifampin may decrease secobarbital levels by increasing metabolism.   NCATS

  • Mol. Mass: 238.29
  • ALogP: 1.35
  • ChEMBL Molecules:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral, Topical
  • Pro Drug: No
5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione | 5-allyl-5-(1-methylbutyl)-2,4,6(1h,3h,5h)-pyrimidinetrione | 5-allyl-5-(1-methylbutyl)barbituric acid | 5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1h,3h,5h)-trione | evronal | hypotrol | immenox | meballymal | quinalbarbital | quinalbarbitone | quinalbarbitone sodium | quinobarbitone | secobarbital | (+-)-secobarbital | (±)-secobarbital | secobarbital sodium | secobarbitalum | secobarbitone | seconal | seconal sodium | seconesin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue